Immix Biopharma (IMMX) logo

Immix Biopharma (IMMX) stock

Cell therapies , market cap $590M

$6.96
-1.14%

Why is IMMX down?

Down 3% on Nov 13, and still 14% under its Nov 12 close.

  • It fell 3% on Nov 13, the session after its Nov 12 SEC filing (read the release).

Sources: Price history, Nov 13, 2026; SEC filing, Nov 12, 2026

−2Dilution 132.1% more shares outstanding than a year ago

Tell me next time IMMX moves

Free account, no card. An optional alert when IMMX moves or its score changes.Pro, $1 for a first month. An optional alert when IMMX moves or its score changes.Pro, 7 days free with a card. An optional alert when IMMX moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on IMMX →1 more reason why IMMX fell on Nov 13, from its filings, with the other side, the timeline, and its peers, for Pro members.
Quality Score
-6
Poor
In its industry
#206of 273
Checks firing
0of 14
Trending down
From 52-week high
-53.9%
under its best in a year

IMMX's Quality Score rose 1 point on Fri, Nov 20, to -6. Gabriel S. Morris (CFO, President) bought $10K on Nov 18, filed Nov 20, and 1 more filing.

Follow IMMX's news. Pro members can get an alert when Immix Biopharma files news, and see its trials, share raises, and its CEO's filings.

Get an alert when IMMX files newsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextDec 12-15, 2026 · In 24 days– Data will be presented on Monday, December 14, 2026 at 11:15 AM CDT – LOS ANGELES, CA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present an NXC-201 abstract at the upcoming American Society of Hematology (ASH) 68th Annual Meeting and Exposition to be held December 12-15, 20Trial data · Press release · Nov 4

Key facts on IMMX

Key facts on IMMX
Holding it back132.1% more shares than a year ago
Latest filing8-K, Nov 12 Reported its quarterly results

What's next

Sat Dec 12: American Society of Hematology…Industry event · date confirmed.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

IMMX catalysts

Coming up

After its last report it closed -2.9%.

3 past catalysts since 2026, with sizes and sources, for Pro members.

What's next for IMMX, and how long its cash lasts

Next step the company has named

Dec 15In 24 days– Data will be presented on Monday, December 14, 2026 at 11:15 AM CDT – LOS ANGELES, CA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present an NXC-201 abstract at the upcoming American Society of Hematology (ASH) 68th Annual Meeting and Exposition to be held December 12-15, 20Trial data · Press release · Nov 4

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
NXC-201

For Pro members: 2 more milestones and 21 filings.

Cash runway

The company says its cash lasts into mid-2028 (8-K, Nov 12).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Jan 9, 2026)
  • At-the-market share sales program (424B5, filed Mar 25, 2026)

For Pro members: 6 raises and their amounts, and the share count against a year ago.

Insiders

CEO Ilya M. Rachman bought 1,408 shares on Nov 18. 1 more insider trade this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Ilya Rachman’s 9 filings and quotes.

Get an alert when IMMX files newsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How IMMX ranks in Biotech

IMMX is #206 of 273 by Quality Score.

How IMMX ranks in Biotech
RankStockQuality Score
206Immix Biopharma (IMMX) logoIMMXImmix Biopharma-6

More in Biotech

When does IMMX report earnings, and what happens after?

Expected to report Fri Mar 12, after the close (in 111 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 1

-2.9%
Nov 12
ReportedGapReaction5
days
Nov 12, 2026After close+2.2%-2.9%-12.8%

IMMX closed higher after 0 of its last 1 report.

Nothing is firing on IMMX right now

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on IMMX, and all 14 on every stock.Get in free →See the top 3 →Start Pro

IMMX RSI on Nov 20: 35.5, below its 50-day and 200-day averages

Not scored

RSI 35.5, MACD below signal, below both averages. Not scored.

The deep dive on IMMX

5 more findings on IMMX, each with its source, for Pro members.

IMMX share count over time

Shares: 2.3 times the count a year ago (to Sep 30).

Shares of IMMX outstanding, as filed
Shares
outstanding
As
of
83.8MOct 30, 2026
71.5MAug 3, 2026
54.4MApr 30, 2026
53MMar 20, 2026
Offerings, shelves, and splits of IMMX, from its filings
From its
filings
Filed
Raised $125M in a sale of shares, about 21% of its market valueSep 29, 2026
Raised $150M in a sale of shares, about 25% of its market valueMay 21, 2026
Set up an at-the-market program for up to $100M of shares, about 17% of its market valueMar 25, 2026
Registered shares for a later sale (S-3)Jan 9, 2026

4 more offerings on file, for Pro members.

IMMX insider trades

2 insiders bought $20K across 2 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyGabriel S. Morris$10KCFO, Presidentat $7.06 on Nov 18, filed yesterday

IMMX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

One more officer or director files at IMMX.

See insider trades by person

Which ETFs hold IMMX?

In ETFs: IMMX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Immix Biopharma

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

21 employeesLos Angeles, CAimmixbio.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on IMMX and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn IMMX's score around: 8 things
  • 11 more filings explained, a plain line each
  • 4 more things pulling IMMX's score down
BreakawayyesterdayGabriel S. Morris bought IMMX$10K at $7.06, filed Nov 20

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: IMMX's Quality Score is -6 (Poor), #206 of 273 in Biotech. Insiders bought $20K in the last 6 months (Form 4).

What does IMMX's Quality Score say?

IMMX scores -6 today, which Breakaway calls Poor. It is #206 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 3% on Nov 13, and still 14% under its Nov 12 close. Shares: 2.3 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is IMMX's Quality Score?

IMMX scores -6 today, which Breakaway calls Poor (below zero). That is #206 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IMMX's -6.

Are insiders buying IMMX?

2 insiders bought $20K across 2 filings in the last 6 months. No open-⁠market sales on record. The newest is Gabriel S. Morris, CFO, President, who bought $10K on Nov 18. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Immix Biopharma: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.